Minneapolis, MN / ACCESSWIRE / October 31, 2014 / PetVivo Holdings, Inc. (OTCPINK: PETV) an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and pet therapeutics is pleased to announce that CEO John Lai was recently interviewed by Metro Cable Network - Channel 6 host Mike Woodley regarding PetVivo's recent progress and future plans.


The Metro Cable Network - Channel 6 will air the interview on all cable network providers in the seven-county metro area of Minneapolis-St. Paul. All cable providers in the seven county Twin Cities metropolitan area carry Metro Cable Network at the accessible channel position of channel 6.


The interview will air three times daily Monday through Saturdays at 8 am, Saturday - Thursday 10 pm and Mondays through Sunday 1 am beginning on Monday November 3rd and continue through the month of November. The interview will reach a potential of 1.2 million viewers per airing to a potential 650,000 homes and businesses. For more information on airtimes and about Metro Cable Network, go to www.MCN6.org.


The interview can also be viewed online at http://youtu.be/jw3GXPlAdxQ


About PetVivo, Inc:


PetVivo, Inc. is a wholly owned subsidiary of PetVivo Holdings, Inc. (OTCPINK:PETV) based in Minneapolis, Minnesota. PetVivo is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and other therapeutics for pets.


PetVivo believes that it can leverage the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.


PetVivo's lead product, Kush(TM) Canine, for the treatment of canine osteoarthritis and Kush(TM) Equine, for the treatment of lameness in horses are both scheduled for launch in 2015. The Kush devices are a small part of a large pipeline of patented animal and human therapeutics developed and manufactured by Gel-Del Technologies, Inc. PetVivo previously announced that PetVivo and Gel-Del Technologies have entered into a binding term sheet for a merger. Under the agreed upon terms Gel-Del will merge with PetVivo Holdings and upon resolution of certain conditions specified as terms, a definitive agreement will consummate the merger.


Forward-Looking Statements:


The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.


For more information, go www.petvivo.com


CONTACT:

John Lai

Chief Executive Officer

PetVivo Holdings, Inc.

Email: info@petvivo.com
Phone: 612-296-7305




SOURCE: PetVivo Holdings, Inc.